Skip to main content

Clinical trial IMpassion 030 (BIG 16-05/AFT-27/WO39391)

A phase III, multicenter, randomized, open-label study comparing atezolizumab (anti-PD-L1 antibody) in combination with adjuvant anthracycline/taxane-based chemotherapy versus chemotherapy alone in patients with operable triple-negative breast cancer

Cancers
Organ Breast
Trial status Trial open for recruitment
Investigator
Trial type
Interventional with experimental drug
Phase Trial phase 3
Academic trial Non
Sponsor Roche
EudraCT Identifier 2016-003695-47
ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03498716
Inclusion criteria Non-metastatic operable. TNBC. Adjuvant. Atezolizumab
Last update